Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Max Schlaak

Showing results (21-30 of 98) with videos related to

Pageof 10
Sort By:
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|May 30, 2025
How to treat primary cutaneous B cell lymphoma - Results from a monocentric cohort study on 98 patientsRohat Cankaya, Pit Leonard Kleiner, Franz Joachim Hilke, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 24, 2021
Risk Factors for Relapse after Intentional Discontinuation of Immune Checkpoint Inhibitors in Melanoma PatientsOana D Persa, Kerstin Schatton, Albert Rübben, et al.
International Journal of Molecular Sciences|February 5, 2020
The Role of Immune Checkpoint Blockade in Uveal MelanomaAnja Wessely, Theresa Steeb, Michael Erdmann, et al.
Cardiovascular and Interventional Radiology|October 28, 2025
Initial Experience with Transarterial Chemoembolization in Metastatic Cutaneous Melanoma Patients with Hepatic Progression on Immune Checkpoint InhibitorsTimo Alexander Auer, Max Schlaak, Gabor Dobos, et al.
Journal of Cancer Research and Clinical Oncology|February 10, 2020
Guidelines for uveal melanoma: a critical appraisal of systematically identified guidelines using the AGREE II and AGREE-REX instrumentTheresa Steeb, Kinan M Hayani, Paul Förster, et al.
European Radiology|November 29, 2019
Single-slice CT measurements allow for accurate assessment of sarcopenia and body compositionDavid Zopfs, Sebastian Theurich, Nils Große Hokamp, et al.
Cancers|July 9, 2022
Development of Lymphopenia during Therapy with Immune Checkpoint Inhibitors Is Associated with Poor Outcome in Metastatic Cutaneous MelanomaDirk Tomsitz, Max Schlaak, Sarah Zierold, et al.
Langenbeck'S Archives of Surgery|January 21, 2023
Oligometastatic disease and visceral resections in advanced malignant melanoma: a propensity-matched analysisAlexander Urbanski, Julia Minnemann, Cornelia Mauch, et al.
International Journal of Clinical and Experimental Medicine|January 8, 2013
(68)Ga-DotaTATE PET-CT followed by Peptide Receptor Radiotherapy in combination with capecitabine in two patients with Merkel Cell CarcinomaMatthias C Schmidt, Klara Uhrhan, Birgid Markiefka, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2025
Multimodal approach predicts relapse upon cessation of immune checkpoint inhibitors in advanced melanomaKa-Won Noh, Yuri Tolkach, Doris Helbig, et al.
Pageof 10

Showing results (21-30 of 98) with videos related to

Sort By:
Pageof 10
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|May 30, 2025
How to treat primary cutaneous B cell lymphoma - Results from a monocentric cohort study on 98 patientsRohat Cankaya, Pit Leonard Kleiner, Franz Joachim Hilke, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 24, 2021
Risk Factors for Relapse after Intentional Discontinuation of Immune Checkpoint Inhibitors in Melanoma PatientsOana D Persa, Kerstin Schatton, Albert Rübben, et al.
International Journal of Molecular Sciences|February 5, 2020
The Role of Immune Checkpoint Blockade in Uveal MelanomaAnja Wessely, Theresa Steeb, Michael Erdmann, et al.
Cardiovascular and Interventional Radiology|October 28, 2025
Initial Experience with Transarterial Chemoembolization in Metastatic Cutaneous Melanoma Patients with Hepatic Progression on Immune Checkpoint InhibitorsTimo Alexander Auer, Max Schlaak, Gabor Dobos, et al.
Journal of Cancer Research and Clinical Oncology|February 10, 2020
Guidelines for uveal melanoma: a critical appraisal of systematically identified guidelines using the AGREE II and AGREE-REX instrumentTheresa Steeb, Kinan M Hayani, Paul Förster, et al.
European Radiology|November 29, 2019
Single-slice CT measurements allow for accurate assessment of sarcopenia and body compositionDavid Zopfs, Sebastian Theurich, Nils Große Hokamp, et al.
Cancers|July 9, 2022
Development of Lymphopenia during Therapy with Immune Checkpoint Inhibitors Is Associated with Poor Outcome in Metastatic Cutaneous MelanomaDirk Tomsitz, Max Schlaak, Sarah Zierold, et al.
Langenbeck'S Archives of Surgery|January 21, 2023
Oligometastatic disease and visceral resections in advanced malignant melanoma: a propensity-matched analysisAlexander Urbanski, Julia Minnemann, Cornelia Mauch, et al.
International Journal of Clinical and Experimental Medicine|January 8, 2013
(68)Ga-DotaTATE PET-CT followed by Peptide Receptor Radiotherapy in combination with capecitabine in two patients with Merkel Cell CarcinomaMatthias C Schmidt, Klara Uhrhan, Birgid Markiefka, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2025
Multimodal approach predicts relapse upon cessation of immune checkpoint inhibitors in advanced melanomaKa-Won Noh, Yuri Tolkach, Doris Helbig, et al.
Pageof 10